GLP1R and COVID-19: Another possible explanationis that, unlike SGLT2i and most GLP1-RA, DPP-4i does not provide cardiovascular protectionin patients with T2DM, and this might affect the prognosis in patients with severe COVID-19,who are particularly burdened by adverse cardiovascular outcomes.32 Stronger evidence will be provided by ongoing randomizedclinical trials on sitagliptin (SIDIACO-RCT, NCT04365517) and linagliptin (NCT04371978,NCT04341935).